Jevtana

cabazitaxel · Sanofi Winthrop Industrie
AUTHORISED IN THE EU

What Jevtana is used for

Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Jevtana
Active substance
cabazitaxel
Disease area
Prostatic Neoplasms
Medicine group
Antineoplastic agents
ATC code
L01CD
Marketing authorisation holder
Sanofi Winthrop Industrie
Authorised in the EU since
2011

Official information

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Jevtana used for?

Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

What is the active substance in Jevtana?

Jevtana contains cabazitaxel.

Who makes Jevtana?

The EU marketing authorisation holder is Sanofi Winthrop Industrie.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.